Antibody-oligonucleotide conjugates (AOCs) —A new wave of drug conjugates

€ 19.99

4.7
(295)
In Magazzino
Descrizione

Antibody–oligonucleotide (Ab–oligo) conjugation

Development of nucleic acid medicines based on chemical technology - ScienceDirect

Webinar: Avidity Biosciences - EXPLORE44 Clinical Trial Investigating AOC 1044 (Feb 2023)

Wells Fargo Adjusts Price Target on Avidity Biosciences to $50 From $55, Maintains Overweight Rating -May 11, 2023 at 11:05 am EDT

Emerging new therapeutic antibody derivatives for cancer treatment. - Abstract - Europe PMC

Antibody-oligonucleotide conjugates (AOCs) —A new wave of drug conjugates

Avidity: An Interesting Diversification (NASDAQ:RNA)

Antibody–Oligonucleotide Conjugates as Therapeutic, Imaging, and Detection Agents

Antibody-oligonucleotide conjugates (AOCs) —A new wave of drug conjugates

SEC Filing

Antibody-Oligonucleotide Conjugates - BOC Sciences

Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf

Oligonucleotide conjugates for therapeutic applications